Soligenix, Inc. (NASDAQ:SNGX) Sees Large Growth in Short Interest

Soligenix, Inc. (NASDAQ:SNGX) saw a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 44,400 shares, an increase of 21.0% from the November 30th total of 36,700 shares. Based on an average daily volume of 105,000 shares, the short-interest ratio is presently 0.4 days. Approximately 1.8% of the shares of the company are short sold.

Institutional Investors Weigh In On Soligenix

A hedge fund recently bought a new stake in Soligenix stock. Stephens Inc. AR purchased a new stake in Soligenix, Inc. (NASDAQ:SNGX) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 46,262 shares of the biopharmaceutical company’s stock, valued at approximately $184,000. Stephens Inc. AR owned approximately 4.69% of Soligenix as of its most recent SEC filing. 3.60% of the stock is currently owned by institutional investors and hedge funds.

Soligenix Stock Performance

Shares of NASDAQ SNGX traded down $0.08 during mid-day trading on Tuesday, hitting $2.83. The stock had a trading volume of 29,526 shares, compared to its average volume of 745,476. The firm has a market cap of $7.10 million, a PE ratio of -0.38 and a beta of 1.79. The company has a 50 day moving average of $3.38 and a two-hundred day moving average of $3.80. Soligenix has a twelve month low of $1.83 and a twelve month high of $19.20.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.